Safety concerns about alosetron [2]

Archives of Internal Medicine

Volumn 162, Issue 1, 2002, Pages 100-101

  Camilleri, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON;

CONSTIPATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; INTESTINE SURGERY; ISCHEMIC COLITIS; LETTER; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CARBOLINES; COLITIS, ISCHEMIC; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0037074315     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
2. Ischemic colitis during treatment with alosetron